Skip to main content
International Wound Journal logoLink to International Wound Journal
. 2023 Jul 12;20(10):4394–4409. doi: 10.1111/iwj.14311

Preclinical study of diabetic foot ulcers: From pathogenesis to vivo/vitro models and clinical therapeutic transformation

Yuqing Du 1, Jie Wang 1,2, Weijing Fan 1, Renyan Huang 1, Hongfei Wang 1,✉, Guobin Liu 1,✉
PMCID: PMC10681512  PMID: 37438679

Abstract

Diabetic foot ulcer (DFU), a common intractable chronic complication of diabetes mellitus (DM), has a prevalence of up to 25%, with more than 17% of the affected patients at risk of amputation or even death. Vascular risk factors, including vascular stenosis or occlusion, dyslipidemia, impaired neurosensory and motor function, and skin infection caused by trauma, all increase the risk of DFU in patients with diabetes. Therefore, diabetic foot is not a single pathogenesis. Preclinical studies have contributed greatly to the pathogenesis determination and efficacy evaluation of DFU. Many therapeutic tools are currently being investigated using DFU animal models for effective clinical translation. However, preclinical animal models that completely mimic the pathogenesis of DFU remain unexplored. Therefore, in this review, the preparation methods and evaluation criteria of DFU animal models with three major pathological mechanisms: neuropathy, angiopathy and DFU infection were discussed in detail. And the advantages and disadvantages of various DFU animal models for clinical sign simulation. Furthermore, the current status of vitro models of DFU and some preclinical studies have been transformed into clinical treatment programs, such as medical dressings, growth factor therapy, 3D bioprinting and pre‐vascularization, Traditional Chinese Medicine treatment. However, because of the complexity of the pathological mechanism of DFU, the clinical transformation of DFU model still faces many challenges. We need to further optimize the existing preclinical studies of DFU to provide an effective animal platform for the future study of pathophysiology and clinical treatment of DFU.

Keywords: animal model, clinical therapeutic transformation, diabetes foot ulcer, pathological mechanism, vivo/vitro models

1. INTRODUCTION

Diabetes mellitus (DM) is a metabolic disease characterized by insufficient insulin secretion or insulin resistance. The International Diabetes Federation (IDF) predicts that the global prevalence of diabetes will increase to 700 million by 2045. 1 Diabetic foot ulcer (DFU) is a serious complication of diabetes. The lifetime incidence of DFU in patients with diabetes is 15%–25%. Coupled with a previous history of foot trauma or infection, the incidence of DFU in diabetics will increase to 19%–34%, 17% of whom will require amputation. 2 , 3 Patients with severe DFU are reported to have more than half the mortality rate as those within 5 years. 4 , 5 The 5‐year risk of death in patients with diabetic foot ulcers is 2.5 times higher than that in patients without foot ulcers. 6 Therefore, the prevention and treatment of DFU is an urgent issue in the management of DM complications.

The pathophysiological basis of DFU is based on a combination of metabolic disorders, hyperglycaemia, hyperlipidemia, high glycoprotein and other factors that lead to peripheral nerve injury and atherosclerosis in patients with diabetics along with external gangrene triggers, which result in skin breakdown of the foot. According to the aetiology, DFU can be broadly classified into three categories: ischemic DFU, infectious DFU and neurological DFU. Currently, DFU treatment includes debridement, anti‐infection, revascularization and hyperbaric oxygen. 7 , 8 Altho ugh the above treatments can promote angiogenesis, improve neurological function or reduce inflammatory response to promote DFU healing, but can not prevent recurrent DFU, or even lead to amputation. With the rise of new technologies such as metabonomics, proteomics and single cell sequencing, the new regimen of DFU therapy is gradually being recognized. 9 , 10

Although the study of human donor tissue is an excellent asset to improve our understanding of the pathogenesis and clinical treatment of DFU, the acquisition of human donor tissue is very rare, and the pathological mechanism of DFU can not be fully demonstrated. The animal model solves these problems and improves the success of clinical transformation to a great extent. Therefore, in this literature review, through the summary and induction of the pathophysiology of DFU, we evaluate the advantages and disadvantages of the animal models of the key pathogenesis of DFU, in order to optimize based on the existing models, so as to improve the effectiveness and transformability of preclinical studies of DFU. In addition, we also discussed the opportunities and challenges of DFU preclinical research transformation.

2. DFU PATHOGENESIS AND REPAIR MECHANISM

DFU pathogenesis is a crucial breakthrough point for the development of DFU animal and in vitro models. Persistent hyperglycemia is the most basic pathological factor in DFU. Hyperglycemia leads to neurological dysfunction that leads to neurogenic DFU. Hyperglycemia can also induce changes in the peripheral arteries of the foot leading to ischemia, increasing the risk of ischemic DFU. In addition, such as long‐term compression of the foot, trauma damage to the skin, poor hygiene habits caused by infection, DFU may also occur. (Figure 1).

FIGURE 1.

FIGURE 1

DFU pathogenesis. Neuropathy, vascular disease and infection are the main pathological mechanisms of DFU. The weakening of sensory, motor and autonomic nerves may lead to dystrophy of Charcot's foot and skin. In addition, arterial stenosis and dyslipidemia may also lead to DFU. External triggers, such as infection caused by trauma, accelerate the development of DFU.

2.1. Influence of vascular lesions on DFU disease progression

Hyperglycaemia causes occlusive‐like changes in large and micro vessels by promoting atherosclerosis, increasing the hypercoagulable state of blood and increasing vascular resistance, microthrombosis and other pathological processes. 11 Furthermore, diabetic microangiopathy is mainly due to endothelial cell damage and capillary basement membrane thickening in the injured capillaries, resulting in luminal narrowing or occlusion and tissue ischemia and hypoxia. However, DFU occurs because of extensive accumulation of microvascular lesions below the knee. In addition, inadequate arterial blood supply delays the healing of the original ulcer. 12

2.2. Influence of neuropathy on disease progression in DFU

Sustained hyperglycaemia leads to the abnormal accumulation of metabolites, causing oedema and nerve cell degeneration, axonal degeneration and subsequent neuropathy such as dermal segmental demyelination and axonal necrosis. 13 Damage to motor nerves alters physical coordination and induces foot deformities and Charcot foot. Moreover, damage to sensory nerves causes repetitive and recurrent damage to the skin of the foot, disrupting skin integrity. Furthermore, autonomic neuropathy leads to loss of sweat and sebaceous gland function, dry and cracked skin and increased susceptibility to breakout and infection. 14

2.3. The inflammatory response is involved in the development of DFU

DFU‐related infections are often a consequence rather than a cause of DFU. Multiple factors, such as diabetic vasculopathy and neuropathy, metabolic disorders and immune deficiencies, play a role in the colonization and invasion of local microorganisms that proliferate in the host tissues to induce an inflammatory response, causing skin damage and subsequently progressing to joint and even bone inflammation. Among them, Staphylococcus aureus infection is the most common. 15 Infection complicates the healing process of DFU, wherein it increases the risk of lower extremity amputation by 50% compared to patients with DFU having no infection. 16

2.4. DFU trauma repair process

Wound repair is a complex biological process consisting mainly of the inflammatory response, cell proliferation and tissue remodelling phases, which are highly regulated. 17 During the early stages of wound healing, neutrophils are recruited to the site of skin injury and are present there for 2–5 days due to the activated complement pathway and protease secretion capacity, thereby killing bacteria and degrading necrotic tissue. Neutrophils release mediators that amplify the inflammatory response and stimulate VEGF and IL‐8 to produce an adequate repair response. Additionally, neutrophils alter the phenotype and cytokine profile expression of macrophages to produce an innate immune response. 18 Approximately three days after injury, macrophages enter the injury site and support the repair process by phagocytosing pathogens and cellular debris 19 and secreting growth factors, chemokines and cytokines. 20 Furthermore, during the proliferative phase of the healing process, granulation tissue formation and vascular network restoration are the main focus. Local fibroblasts are directed to the defect site via migration along the fibrin network, and then re‐epithelialization occurs around the wound edges. In addition, cytoskeletal actin fibres aggregate at the site of the wound and new adhesion patches are formed at the integrin‐mediated extracellular matrix. Following this, neovascularization and angiogenesis are activated by capillary sprouting, 21 wherein growth factors bind to receptors on endothelial cells and activated endothelial cells proliferate and migrate into the wound and form small tubular ducts that interconnect to form a vascular ring. Thereafter, the new vessels differentiate into arteries and small veins and mature by recruiting pericytes and smooth muscle cells to further stabilize their walls. Finally, blood flow initiation completes the angiogenesis process. The final stage of wound healing is remodelling, wherein granulation tissue formation ceases owing to the apoptosis of cells. The new collagen matrix becomes more oriented, cross‐linked and multiple myofibroblast attachment formation help to reduce the scar surface (Figure 2).

FIGURE 2.

FIGURE 2

The DFU the process of repair. DFU healing is a chronic wound repair process, including inflammation, proliferation and remodelling overlap, and finally ulcer healing.

Different cells and factors are involved in different stages of wound healing. It can be seen that the pathogenesis of human DFU and wound healing are very complex. For different pathological basis, different preclinical models should be established to explore. Meanwhile preclinical DFU models are essential for the development of new therapeutic agents and devices. The selection of appropriate animal models based on the research question is vital in translating the results of basic research into clinical practice.

3. DM ANIMAL MODELS

When studying DFU animal models, a DM animal model should be first established. The current methods of preparing DM animal models mainly include spontaneous mutagenic animal models and inducible animal models. 22 , 23 Spontaneous mutagenic animal models mainly include ob/ob murine models, db/db murine models and non‐obese diabetes (NOD) murine models, whereas induced animal models include high‐fat diet induction, Streptozocin (STZ) induction, tetraoxine induction and high‐fat diet combined with STZ or tetraoxine induction.

Rats and mice are commonly used as animal models; however, larger animals such as dogs or pigs have also been studied. 24 , 25 With the advent of gene editing technology, knockout rodents have become a powerful tool for analysing specific gene functions. Moreover, owing to the high cost of large animal models, gene editing technology is widely used in rodents, such as the db/db diabetic mouse model. Furthermore, in terms of detection methods, the market is mostly dominated by antibody kits for rodents, with antibody kits for large animal models being scarce. Therefore, rodents are an important tool for exploring the pathogenesis and treatment of DFU.

3.1. Spontaneous mutagenic mouse models

Despite advancements in the approaches and techniques to construct animal models, many spontaneous mutagenic animal models are still preferred owing to their good specificity and tendency to produce reproducible models of glucose metabolism defects, which are more consistent with biological traits (Table 1).

TABLE 1.

DFU spontaneous or transgenic rodent models.

Type Type of diabetes Duration of hyperglycaemia References
NOD mice Type I DM 12–30 weeks of age 26, 27
ob/ob (C57BL/6J‐Lepob) mice Type II DM 7 weeks of age 28, 29
db/db (C57BL/KsJ) mice Type II DM 8–10 weeks 30, 31
GK rat Type II DM 8–14 weeks of age 32, 33
OLETF rats Type II DM 24–65 weeks of age 34
ZUCKER (ZDF) rat Type II DM 5–10 weeks of age 35, 36

Abbreviations: DM, Diabetes mellitus; GK, Goto Kakizaki; OLETF, Otsuka Long Evans Tokushim fat.

Since the introduction of spontaneous hyperglycaemic mouse models, various mouse lines have been investigated, including NZO mice, ob/ob mice and Kimba mice. However, current spontaneous mouse models used for DFU analysis are mainly NOD mice, ob/ob mice and db/db mice. NOD mice are the most commonly used spontaneous model of T1D. They develop at 3–4 weeks of insulitis, which subsequently leads to subclinical cell destruction and insulin reduction. The final establishment of diabetes occurs between 12–30 weeks of age, and animals can survive for several weeks without insulin injections. 37 , 38 Furthermore, the ob/ob and db/db mice are type 2 diabetes (T2D) animal models. ob/ob mice develop hyperglycaemia at 7 weeks of age, whereas db/db mice develop hyperglycaemia at 8–10 weeks of age. In ob/ob mice, leptin levels decrease and obesity increases due to spontaneous mutations in the obesity (ob) gene. Their diabetes‐like syndrome is characterized by hyperglycaemia, mildly impaired glucose tolerance, severe hyperinsulinemia, low fertility and impaired wound healing. 39 , 40 The db/db mice exhibit the same characteristics as the ob/ob mice, but the mutation is located in the leptin receptor gene in the db/db mice and is therefore insensitive to leptin treatment. Notably, literature analysis reveals that db/db mice are more widely used than ob/ob mice as they have a systemic phenotype closer to human T2DM and exhibit severe damage in terms of chronic trauma. 41 , 42

Zucker diabetes fat (ZDF) rats, Otsuka Long Evans Tokushim fat (OLETF) rats and Goto Kakizaki (GK) rats have been reported to develop T2D. ZDF rats developed hyperglycaemia earlier than the other rat models between 5 and 10 weeks of age. The ZDF rat line was originally an obesity disease model selected from Zucker (fa/fa) rats with diabetes phenotype. 43 Male OLETF rats showed elevated glucose and insulin at 24 weeks of age, which increased with age. The incidence of hyperglycaemia and hyperinsulinemia at 65 weeks of age was as high as 90%. 44 OLETF rat model showed low cholesterol, high triglyceride and diabetes. GK rats showed elevated blood glucose levels at 8–14 weeks of age, which manifested abnormal insulin secretion and insulin resistance; however, blood lipids were normal. 45 , 46

3.2. Induction method

Although there are many methods of diabetes induced model, including chemical drug induction (STZ, Alloxan, Ferric nitrilotriacetate and Dithizone) virus induction (coxsackie B virus, encephalomyocarditis virus, Kilham rat virus) and so on. However, after summarizing the literature related to DFU animal model, it is found that the methods of inducing DM animal model in DFU are only STZ, Alloxan and high fat diet (Table 2).

TABLE 2.

Common diabetic induced modelling methods in DFU animal models.

Moulding method Species Dosing method Diagnostic criteria
STZ Rat Single dose IP 45 mg/kg, 47 40 mg/kg, 48 55 mg/kg, 49 50 mg/kg, 50 special ones are single IP 100 mg/kg 51 Blood glucose level ≥ 16.7 mmol/L
Mice

Single IP STZ 50 mg/kg 52

Continuous 5 days IP STZ 50 mg/kg 53

Blood glucose ≥300 mg/dL/glucose level ≥ 16.7 mmol/L
Tetraoxine Rat Tetraoxapyrimidine IP 120 mg/kg 54 72 h blood glucose ≥250 mg/dL
Mouse Single Tetraoxapyrimidine IP 150 mg/kg, 55 180 mg/kg 56 Blood glucose level ≥ 250 mg/dL
High‐fat feed + STZ Rat After 8 weeks of HFD, IP STZ 35 mg/kg 57 ; 4 weeks of HFD, IP STZ 30 mg/kg 58 Blood glucose level ≥ 16.7 mmol/L
Mouse HFD for 6 weeks +IP STZ 45 mg/kg 59 ; high‐fat diet for 1 week with five consecutive days of IP IP STZ 50 mg/kg 60 Blood glucose level ≥ 16.7 mM

Abbreviations: HFD, high‐fat feed; IP, intraperitoneal injection.

STZ is currently the most widely used induction agent for modelling, which selectively causes islet B‐cell necrosis and insulin deficiency by activating autoimmunity, resulting in elevated blood glucose level and a non‐insulin‐dependent state. Recently, it has been reported that multiple low‐dose injections of STZ to neonatal rats can induce the typical ‘three more and one less’ symptoms in adult rats. 61 STZ was injected usually intraperitoneally into rats for modelling. STZ was rarely injected into the tail vein of rats to destroy islet cells, thereby obtaining a diabetic model. Notably, an accepted standard for STZ injection dose remains elusive. For example, He et al. was successful after a single intraperitoneal injection of different STZ doses 62 , 63 whereas Liao et al. were successful after five consecutive intraperitoneal injections of STZ moulding. 64 , 65

A high‐fat diet‐induced T2DM animal model was first reported in 1947. High‐fat and high‐protein foods have a low GI, which can lead to excessive fat and protein intake, causing atherosclerosis, hyperlipidaemia, hypertension, insulin resistance and diabetes. However, a DFU model is yet to be prepared for HFD‐induced diabetes alone, and it is often used in combination with the STZ induction method, thereby constructing diabetic rat models in a shorter period and improving the success rate and stability of modelling.

Alloxan selectively reduces insulin sensitivity by inhibiting the secretion of glucose kinase (GCK) from pancreatic islet J3 cells. Alloxan also triggers the necrosis of pancreatic islet l3 cells by producing reactive oxygen clusters, leading to decreased insulin secretion, elevated blood glucose and ketosis. 66 Owing to the toxic damage caused by Alloxan to the liver and kidney and the high rate of ketosis, ALX has now been gradually replaced by STZ. 67

4. DFU ANIMAL MODELS

After the successful modelling of DM animal models, the main ulcer modelling methods are currently the ischemic ulcer model, neuropathic ulcer model and infectious ulcer model, which are based on the pathogenesis of DFU neuropathy, vascular lesion and infectious lesion, respectively (Table 3).

TABLE 3.

Simulation of Diabetic foot ulcer (DFU) pathogenesis animal models.

Classification of DFU animal models Moulding method Assessment criteria
Ischemic animal ulcer model Resection of superficial femoral artery only 68 Plantar skin perfusion, laser Doppler measurement
Neuropathic animal ulcer model Resection of the iliac artery, femoral artery, popliteal artery and saphenous artery 3 weeks postoperatively 69 Monofilament (10 g) test, paw retraction test after thermal stimulation, paw retraction test after cold stimulation, motor nerve conduction velocity, the sensory nerve conduction velocity of animals
Nerve ligation method, nerve resection method and nerve extrusion method. Clamping of the sciatic nerve approximately 0.5 cm above the complete bifurcation for 1 min followed by suturing for seven days 70 , 71
Dissection of the sciatic and femoral nerves 72
Infected diabetic ulcer model Nerve squeezing method 73 Bacterial colonies recovered from tissues for bacterial culture
Staphylococcus aureus 74

4.1. Ischemic animal ulcer model

Based on the pathological mechanism of lower limb ischemia, a DFU model can be established by simulating hind limb ischemia through vascular ligation and vessel resection. A longitudinal incision is made in the groin and the artery is resected. However, controversy remains over the choice of a resected artery, with most studies choosing to resect or ligate only the femoral artery. 75 , 76 , 77 Ligation of the femoral artery alone has been reported to cause acute severe ischemic necrosis, with pathological changes that differ significantly from the chronic ischemic state of the diabetic foot, which is dominated by small and medium‐sized arterial lesions. The femoral artery in rats has numerous branches such as the spinous superficial iliac artery, the muscular branch, the superficial abdominal wall artery, the uppermost knee artery and the saphenous artery, in addition to the continuation as the popliteal artery. Herein, the blood flow values were not significantly altered when the femoral artery was treated alone, whereas the blood flow values decreased significantly after removing its branch arteries. Nishimoto removed the external iliac artery, the femoral artery and a portion of the saphenous artery to the knee. 78 Laser Doppler (LDPI) measurement of lower extremity blood flow 79 , 80 or skin perfusion 81 , 82 to assess the relative objectivity of animal models of ischemia can be used as a reference index to judge the differences in ischemic models in repeated trials. Moreover, LDPI is significant in the clinical evaluation of the prognosis of patients with ischemic diabetic foot, but the subjective variability in the determination of animal models is vast and is therefore not recommended as the main indicator for evaluating ischemia in animal models.

4.2. Animal model of neuropathic ulcers

Since the 1960s, researchers have developed various painful diabetic neuropathy (PDN) models using dietary induction, chemical induction and genetic modification; however, the modelling methods for DFU caused by peripheral neuropathy are still based on nerve destruction, which currently includes nerve ligation, nerve excision and nerve extrusion. Jin et al. report a ligated nerve approach to establish a diabetic neuropathy model. The nerve ligation method was mainly prepared as a diabetic model using STZ injection. The sciatic nerve of rats was freed, clamped with haemostatic forceps at approximately 0.5 cm above the complete bifurcation of the sciatic nerve for 1 min and then sutured. After seven days, spontaneous ulcers were observed in the right foot of some rats. 83 , 84 The sciatic nerve ligation method accelerated diabetic peripheral neuropathy and clarified the pathological indexes. However, the spontaneous rate of ulcers in rats is low and the time to form ulcers is long, thereby requiring a combined approach with the method of damaging skin tissue to shorten the time of ulcer development.

In addition, neurectomy methods exist. Lu et al. chose SD rats as experimental animals. After anaesthesia surgery, a part of the spinal cord was exposed between Th10‐12 and the sciatic and femoral nerves were cut for better expsoure. 85 Shu et al. chose to cut the T9‐L1 nerve root for modelling. 86 The neurectomy method has a shorter modelling time and a higher ulcer formation rate. It is also suitable for repairing nerve damage in diabetic animal studies; however, the neuropathy triggered by severing the nerve is not consistent with the clinical DFU pathology mechanism. Furthermore, Karkada et al. used the nerve crush method to induce nerve injury by surgically separating the sciatic nerve after inducing a DM rat model and inflicting a crush injury using haemostatic forceps. 87 This model can also shorten the modelling time and has increased economic benefits.

Common methods to detect indicators of diabetic peripheral neuropathy include the single filament (10 g) test, paw retraction test after thermal stimulation and paw retraction test after cold stimulation. 88 The motor nerve conduction velocity and sensory nerve conduction velocity of the animals are also indicators to verify the success of the model. In conclusion, although nerve injury is an ideal model for studying diabetic foot neuropathy, there remains a gap between the model's reflection and a realistic reflection of DFU caused by human diabetic neuropathy. 89 Therefore, the preparation of a DPN‐type diabetic foot model with similar physiopathology to that of humans is a research hotspot. Further studies are required to urgently develop therapeutic drugs for such diseases.

4.3. Infected diabetic ulcer model

Infectious animal ulcer models have also been used as an important model for diabetic ulcers. 90 , 91 Among the infectious causative agents, the three main groups include Gram‐negative bacteria, Gram‐positive bacteria and fungi, with Staphylococcus aureus (MRSA) as the most common causative agent. 92 , 93 After Garedew Kifelew established a wound model in diabetic mice, MRSA suspension was applied to the wound surface. MRSA suspension was applied to the wound surface and wrapped with gauze to successfully establish an infected ulcer model. 94 Rich et al. established a NOD mouse model of S. aureus‐infected hind paws and isolated the PS80 S. aureus strain. After anaesthetizing DM mice, 10 μL of S. aureus suspension was injected into the hind limbs. 95 Similarly, Chhibbe et al. also successfully established a NOD mouse model. 96 El‐Naggar et al. established an animal model of Pseudomonas aeruginosa DFU infection. 97 In the infection model, its success was verified mainly using the bacterial culture of foot tissue or bacterial colonies recovered from the tissue. 98 , 99 Albac et al. confirmed the role of phages in a mouse model of S. aureus diabetic foot infection and laid the foundation for the use of biofilms for trauma infection. 100

DFU trauma infections have a high bacterial complexity with the presence of symbiotic microorganisms of different ecological niches that closely resemble biofilm growth environments. 101 , 102 Zhao et al. in 2010 pioneered an experimental diabetic model to explore the presence of biofilms in diabetic db/db mice, wherein Pseudomonas aeruginosa or S. aureus biofilms delayed wound healing and diabetic condition slowed healing and increased biofilm thickness. 103 , 104 Nonetheless, robust animal models of wounds that can reproduce the clinical situation and biofilm composition are yet to be constructed.

4.4. Animal models of diabetic ulcers that mimic clinical signs

The establishment of such ulcer models is simple, easy but time‐consuming and allows the ready visualization of epidermal neogenesis, migration and granulation tissue formation. This facilitates the quantitative analysis of wounds and further in vivo efficacy evaluation. However, the skin ulcer models established using this method only mimic the external state of the diabetic foot but not of the spontaneous ulcers. Nonetheless, many studies have induced diabetic ulcers on the back or trunk of animals. 105 , 106 , 107 Therefore, the ulcers formed in this manner only result in delayed wound healing and are not a true representation of DFU (Table 4).

TABLE 4.

Methods and characteristics of DFU animal models.

Modelling category Moulding methods and indications, advantages and disadvantages

Full skin excision model

graphic file with name IWJ-20-4394-g003.jpg

Perforated instrument for obtaining full‐layered cylindrical ulcers 108

Marking trauma area on the rat skin and then directly cutting out the marked area skin 109

Study of topical dressings and drugs suitable for diabetic foot
Quantitative analysis of trauma area
Highly manoeuvrable, less time‐consuming, regular ulcer pattern and controlled area

Circumferential splint model

graphic file with name IWJ-20-4394-g004.jpg

After establishing the wound on its dorsal surface, a 0.5‐mm‐thick circular splint was fixed around the wound using a nylon thread, and the splint was adequately adhered and secured with sutures 110 , 111
DFU epithelialization differences and granulation growth were assessed.
In addition, the contractile mechanism of healing was negated, the chronic wound healing process was prolonged and clinical outcomes were more accurately translated.
Animals interfere with the results by scratching or biting the suture line. In addition, anchoring of the suture line triggers inflammation

Skin compression method

graphic file with name IWJ-20-4394-g001.jpg

Magnetic sheets were placed on both sides of the ulcerated skin and pressure was applied continuously for several hours per day depending on the amount of pressure on the sheet, and uniform brown patches of skin were observed after 3–4 days of repetition, indicating successful modelling 107 , 112

Small lead beads were attached to the right leg of the rat so that 5% of the animal's body weight was loaded onto the plantar surface of the heel skin 68

Ischemic combined pressure injury‐induced DFU model
Replicates the ischemia–reperfusion principle, with pathological products of the necrotic region such as necrosis and leukocyte aggregation, which is similar to DFU
Cannot be applied to DFU. It also lacks simultaneous blood flow monitoring of the skin at the pressure site and cannot directly account for the alternating process of ischemia and reperfusion in the skin at the pressure site

Skinfold chamber model

graphic file with name IWJ-20-4394-g005.jpg

Implantation of a skinfold chamber and use of a skin perforator to create a lesion in the dorsal skin muscle (m. panniculus carnosus). An external circular rim was created, and the wound was covered with a coverslip and secured with a snap ring 113
DFU angiogenesis and microcirculation were studied
Meets the need for continuous in vivo measurements and allows analysis of different tissues and textures
Large size, carry the coverslip and snap inconveniently, risk of stretching of the skin and injury to the dorsal muscles

Scalding model

graphic file with name IWJ-20-4394-g006.jpg

A deep second‐degree scald model of SD diabetic rats was prepared using an electrothermal scalding instrument 114

Immersion in an 80°C water bath for 6 s induced a scalding model in DM rats 115

Related studies on diabetic peripheral neuropathy are available.
Simulated DFU with obvious signs of exudation, redness and swelling
Ulcer morphology and extent are difficult to control, not easy to quantitatively measure and analyse, involve more factors than other existing models and have limited clinical applications

5. DFU IN VITRO MODEL CONSTRUCTION

5.1. 2D cell culture model

The 2D scratch test has been used as a test model for various potential DFU therapies. Prior to wound induction, cells are cultured under hyperglycaemic conditions to mimic the hyperglycaemic microenvironment of DFU. Avitabile et al. attempted to establish a DFU model by extracting fibroblasts and keratin‐forming cells from patients with diabetics to construct a diabetic microenvironment similar to that observed in DFU. 69 In addition, studies identified keratin‐forming cells K16, 116 glycosylation of skin collagen 117 and age as relevant markers of DFU. However, the translation of these markers requires further study as the complexity and holistic nature of the wound healing process in DFU are often overlooked. Nonetheless, owing to the simplicity of the 2D in vitro model approach, it has potential therapeutic value.

5.2. Three‐dimensional (3D) DFU model

Three‐dimensional cell culture (TDcc) refers to the in vitro co‐culture of cells with materials that have a 3D structure, which allows the cell to migrate and grow in a spatially 3D manner. For DFU models, 3D models are preferred over animal and 2D cell models because their structures are physiologically similar to natural human skin. Moreover, the physiological features found in vivo can be reconstructed using the 3D assembly technology. 118 Nonetheless, normal 3D wound models have been used as a reference to develop 3D hyperglycaemic wound models in DFUs. For example, Maione et al. took fibroblasts derived from patients with DFU and generated 3D hyperglycaemic wound models of DFU, revealing phenotypes commonly found in DFU, including impaired angiogenesis, re‐epithelialization, granulomatous proliferation and extracellular matrix deposition. 70 Ozdogan et al. applied human umbilical vein endothelial cells (HUVECs) and keratin‐forming cells from patients with T2D to construct a 3D diabetic wound model. 71 The DFU 3D model is being further investigated by adding cellular complexity, thereby providing better insight into its similarity with clinical DFU appearances. Limitations of this method include limited availability of DFU tissue source, the possibility of bacterial infection biologically and the short growth potential and lifespan of cell cultures, thereby prolonging the establishment of DFU cell models.

6. RESEARCH AND CHALLENGES OF DFU TRANSFORMATION

6.1. Transformation results of preclinical research on DFU

Tissue repair is prevalent in all multicellular organisms. Therefore, the mechanism of wound healing can be studied using animal models. Preclinical models are the first critical aspect of clinical translation. Several preclinical models of DFU have been used in the development of various clinical treatment strategies for DFU.

6.1.1. Medical dressings

DFU is a refractory wound and dressings have become an essential wound management tool. Since each stage of the DFU healing process has a different wound microenvironment, appropriate dressings should be selected according to DFU pathogenesis, dressing properties and dynamic wound change process. In an animal model of infectious DFU, silver ion dressings were demonstrated to have good anti‐infective and bactericidal effects and were superior to other dressings when applied during the inflammatory phase. 72 The clinical effectiveness of ionic silver dressings was also found to be superior to that of Algosteril® calcium alginate (CA) dressings, displaying a reduction in ulcer depth of approximately twice that of CA treatment in clinical practice. Hydrocolloids are suitable for granulation and epithelialized wounds due to their exudate absorption properties and can also be used in necrotic wounds to promote wound debridement. 73 Furthermore, dressings of chitosan and its derivatives have also been used in the STZ diabetic rat model, demonstrating accelerated tissue collagen deposition and skin re‐epithelialization. 119 , 120 In dressings using re‐hyaluronic acid and its derivatives, the promotion of granulation tissue formation, cell proliferation and vascularization to accelerate wound closure was demonstrated in the STZ diabetic rat model. 121 Additionally, collagen‐based dressings exhibited antioxidant capacity, improved cell proliferation and pro‐capillary formation in db/db mice or STZ diabetic rats. 122 Although various dressing types are available, the data is insufficient to recommend any specific dressing type. Thus, more preclinical studies are needed to develop and validate dressing types.

6.1.2. Stem cell therapy

Recently, cellular therapy has emerged as an attractive alternative for the treatment of patients with DFU. 123 Several studies have applied ischemic DFU or infectious DFU animal models or skin perforation models to support cell therapy. 124 , 125 Transplantation of stem cells into DFU wound‐specific sites leads to the secretion of chemokines, decreases the level of proinflammatory signals from immune cells and mesenchymal stem cells and promotes the conversion of macrophages from inflammatory M1 to anti‐inflammatory M2 phenotype via paracrine signalling. Moreover, the healing process tends to lean toward regenerative rather than the fibrotic repair of traumatic tissue. 74 Additionally, reducing apoptosis and modulating the immune response drive each step of DFU healing, such as inflammation, granulo‐proliferative phase, angiogenesis and re‐epithelialization. The use of adipose stem cells, human umbilical cord stem cells, bone marrow stem cells, peripheral blood mononuclear cells and stem cell derived vesicles or combination therapies with mesenchymal stem cells (MSCs) have been reported to accelerate wound healing in DFU models. 126 Notably, with the development of animal models, cell therapy as a regenerative medicine is progressively being used in techniques for isolating, expanding and transplanting stem cells, which can aid in the repair of various chronic wounds.

6.1.3. Growth factor therapy

Growth factors are involved in every stage of wound healing and have shown a regulatory effect on DFU wounds. Among them, platelet‐derived growth factor (PDGF) and transforming growth factor‐beta (TGF‐b) have chemotactic and mitogenic effects on inflammatory cells, whereas fibroblast growth factor (FGF) has chemotactic and mitogenic effects on fibroblasts. Moreover, both PDGF and EGF promote re‐epithelialization. Furthermore, vascular endothelial growth factor (VEGF) induces angiogenesis. Growth factor therapies have shown promising results in small animal models of DFU in vivo. Mellin et al. in 1994 reported that acidic fibroblast factor (aFGF) accelerated skin wound healing in diabetic mice. 127 Philip et al. found that in the early stages of healing in animal models of diabetic ulcers, the gene expressions of VEGF, FGF‐1 FGF‐2 and TGF‐β decreased. 128 Seong et al. developed structurally stable EGF and basic fibroblast factor (bFGF) ‐poor products that increased collagen accumulation and stimulated DFU wound closure. 129 Additionally, the combination of multiple growth factors showed unique advantages over single growth factors in wound repair. Nonetheless, more DFU preclinical models are needed in the future to evaluate the therapeutic efficacy of growth factors and screen for more appropriate products with the aim of benefiting patients with DFU ulcers.

6.1.4. 3D bioprinting and pre‐vascularization

3D bioprinting has emerged as a bioengineering technology involving the dispensing of cell‐laden bioinks through printing nozzles to allow the positioning of various cells in predefined spatial arrangements and cell densities. This restores the proper stratification of the skin, thereby enhancing the proliferation and migration of multiple cell types and promoting better healing outcomes. Additionally, skin bioprinting technology can produce skin‐like organs that can grow implantable hair follicles, neurons, dermis and epidermis. Tânia et al. transplanted skin grafts made using 3D printing technology into an immunodeficient mouse wound model that could rapidly invade host microvasculature and epidermal tissue. 130 Rajesh et al. topically applied an extracellular matrix prepared from autologous homologous adipose tissue using 3D bioprinting to the wounds of patients with DFU, revealing that it could accelerate epithelialization formation. 131

Capillaries can be formed and assembled in 3D printed scaffolds by encapsulating human blood‐derived endothelial colony‐forming cells and MSCs in 3D gelatin methacrylate (GelMA) to produce dense microvessel systems. Recently, Turner et al. combined functionalized scaffolds with GelMA to generate a vascular structural body for improved wound healing, forming strips of natural micro vascularization in in vitro experiments of wound healing. 132 Furthermore, Zhang et al. developed an in vitro 3D bio‐printed tissue model with better lumen formation, finer actin networks and well‐aligned matrix fibres than previously reported models. 133 Recently, numerous studies have reported on 3D‐printed angiogenesis experiments that were performed by simulating the hyperglycaemic microenvironment in diabetic wounds. 134 , 135 However, the remains a lack of standardization in clinical and preclinical trials. Thus, further research on DFU‐specific healing is needed as new technologies such as skin bioprinting remain to be tested on animal models of DFU.

6.1.5. Prospects of Traditional Chinese Medicine (TCM) preparations for DFU treatment

Compared with Western medicine, the treatment of DFU with TCM is rich and diverse and is mainly divided into internal herbal compound treatment and external treatment. Internal compound Chinese medicine is mainly based on the clinical symptoms of the patient while the treatment is based on evidence. The external treatment of DFU has a long history in Chinese medicine, with records dating back to 700 BCE. Many traditional treatment methods are still in use, such as TCM debridement, fumigation, soaking and washing and external application, which have achieved good clinical results. With the advancements in modern medical technology, herbal extracts or herbal compounds with the ability to promote skin healing are being considered. Lu et al. reported that the treatment of DFU rats with chemotherapy and muscle growth cream increased the rate of wound healing. 136 Our research group developed a Zizhu ointment (ZZO), which has good clinical efficacy when applied topically to patients with DFU. 137 In addition, ZZO was found to accelerate wound healing in diabetic mice by inhibiting the activation of the Notch4 signalling pathway, promoting the polarization of M2 macrophages and reducing the inflammatory response. 137

6.2. Challenges of transformation

The selection of an appropriate model in DFU research is tricky. Moreover, a true translational model will be a reorganization of multiple factors to reproduce the clinical situation, such as the age, sex and underlying disease of the clinical patient. 138 Another difficulty when using DFU animal models is the lack of accurate replication of human conditions. Therefore, the selection of an appropriate DFU model based on the scientific questions posed by the study and the multifaceted assessment of DFU healing outcomes are necessary for better clinical translation. Although the rat is currently the most commonly used animal model for DFU, other animal models are also studied. Moreover, the murine flaccid skin and high‐density hair density do not reflect the structure of the human skin as wounds heal mainly in a contracted form. Furthermore, the rabbit ear wound model overcomes this contraction problem, but its limitations include limited genetic susceptibility to handling and lack of species‐specific reagents. 139 The guinea pig, which has an inadequate diet due to its inability to produce endogenous vitamin C, can be used to study the role of collagen in wound healing. 140 Similarly, zebrafish can be used to study DFU regeneration by re‐epithelialization and granulation. 141 Nonetheless, it is a relatively underdeveloped animal model. Pigs and humans have the most similar skin structure, hair density and physiology of wound healing and can mimic clinical interventions well; however, such models are expensive and are difficult to maintain in preclinical studies. Thus, the choice of model depends largely on the stage of application of the new method or the direction of the problem being investigated.

Morbidity and mortality of human DFU increase with age, yet most studies use relatively young animals and lack underlying disease. Comparative studies by wound healing in aged rats versus adult rats have shown reduced immunostaining for fibronectin and delayed inflammatory response, epithelial reformation and extracellular matrix components in the wounds of aged mice. 142 These data indicate that age is an important predictor of DFU prognosis. Although a small number of studies have addressed the effects of ageing on DFU, 143 the generalization of animal models of DFU is yet to be achieved. Moreover, current studies focus on animal models of DFU in adult rats rather than older rats.

Notably, quality control factors in preclinical experimental processes need to be strengthened to avoid preclinical result bias. Even though current experimental equipment and methods have achieved a lot in simulating human DFU in terms of high glucose state and trauma injury, they still cannot realistically reproduce human DFU events. Studies have also found that the bacteria contained in pus extracts triggered by traumatic infection models are too far removed from the human DFU process. 144 Additionally, anaesthetic drugs are inevitably used during animal experiments to complete the experiments, which might have some neuroprotective effects on the modelling and healing process of diabetic neuropathic ulcers. Recently, animal experimental studies have begun to focus on animal physiological monitoring, including changes in blood pressure, blood gas, heart rate, body temperature, body weight and even electroencephalogram and electrocardiogram. These changes are important for the further evaluation of the experimental results. Additionally, the evaluation of long‐term experimental results is scarce in current studies, and it is vital to evaluate the long‐term effects of DFU to reduce the amputation rate and improve the quality of life. Thus, improving the evaluation of treatment effects in animal models involving these influencing factors can aid in enhancing the clinical translation of DFU.

7. CONCLUSIONS

In the past decades, many important advances have been made in preclinical studies of DFU that have aided in the better understanding of DFU pathogenesis and the development of effective therapeutic approaches; however, gaps do remain between the accurate reflections of the human diabetic foot and these preclinical models. The complex DFU wound healing process involves pathogenesis and the systemic dysregulation of the whole body and its comorbidities, thereby hindering the identification of therapeutic targets and clinical trial design. For now, within reasonable costs, multiple or multivariate models can be applied to increase the credibility of preclinical studies or specific preclinical models can be selected based on a particular pathological mechanism. Thus, the greatest challenge is to develop a DFU model that closely resembles the human environment in the healing of diabetic ulcers, which has therapeutic potential in clinical settings.

FUNDING INFORMATION

This study was partially supported by a research grant from National Natural Science Foundation of China (No.82284528) and Shanghai Municipal Science and Technology Commission (21Y21920200).

CONFLICT OF INTEREST STATEMENT

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Du Y, Wang J, Fan W, Huang R, Wang H, Liu G. Preclinical study of diabetic foot ulcers: From pathogenesis to vivo/vitro models and clinical therapeutic transformation. Int Wound J. 2023;20(10):4394‐4409. doi: 10.1111/iwj.14311

Yuqing Du and Jie Wang have contributed equally to this article.

Contributor Information

Hongfei Wang, Email: w15801738507@126.com.

Guobin Liu, Email: drlguobin@126.com.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable for this article.

REFERENCES

  • 1. Seaton M, Hocking A, Gibran NS. Porcine models of cutaneous wound healing. ILAR J. 2015;56(1):127‐138. [DOI] [PubMed] [Google Scholar]
  • 2. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376(24):2367‐2375. [DOI] [PubMed] [Google Scholar]
  • 3. Lipsky BA, Senneville E, Abbas ZG, et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36(Suppl 1):e3280. [DOI] [PubMed] [Google Scholar]
  • 4. Morbach S, Furchert H, Groblinghoff U, et al. Long‐term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade. Diabetes Care. 2012;35(10):2021‐2027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Huang YY, Lin CW, Yang HM, Hung SY, Chen IW. Survival and associated risk factors in patients with diabetes and amputations caused by infectious foot gangrene. J Foot Ankle Res. 2018;11:1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Edmonds M, Manu C, Vas P. The current burden of diabetic foot disease. J Clin Orthop Trauma. 2021;17:88‐93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Wenhui L, Changgeng F, Lei X, Baozhong Y, Guobin L, Weijing F. Hyperbaric oxygen therapy for chronic diabetic foot ulcers: an overview of systematic reviews. Diabetes Res Clin Pract. 2021;176:108862. [DOI] [PubMed] [Google Scholar]
  • 8. Fan W, Yang B, Hu X, Yang X, Shi C, Liu G. Safety and efficacy of larval therapy on treating leg ulcers: a protocol for systematic review and meta‐analysis. BMJ Open. 2020;10(10):e039898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Zhang WQ, Tang W, Hu SQ, et al. C‐reactive protein and diabetic foot ulcer infections: a meta‐analysis. J Tissue Viability. 2022;31(3):537‐543. [DOI] [PubMed] [Google Scholar]
  • 10. Lin J, Song H, Liang M, et al. Advances in the study of OSA and diabetic foot. Diabetol Metab Syndr. 2022;14(1):70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Waheed FNM, Vangaveti VN, Malabu UH. Ischemic heart disease and its risk factors in patients with diabetic foot ulcers: a systematic review and meta‐analysis. Diabetes Metab Syndr. 2022;16(2):102414. [DOI] [PubMed] [Google Scholar]
  • 12. Kandregula B, Narisepalli S, Chitkara D, Mittal A. Exploration of lipid‐based nanocarriers as drug delivery Systems in Diabetic Foot Ulcer. Mol Pharm. 2022;19(7):1977‐1998. [DOI] [PubMed] [Google Scholar]
  • 13. Volmer‐Thole M, Lobmann R. Neuropathy and diabetic foot syndrome. Int J Mol Sci. 2016;17(6):917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Reeves ND, Orlando G, Brown SJ. Sensory‐motor mechanisms increasing falls risk in diabetic peripheral neuropathy. Medicina (Kaunas). 2021;57(5):457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Louiselle AE, Niemiec SM, Zgheib C, Liechty KW. Macrophage polarization and diabetic wound healing. Transl Res. 2021;236:109‐116. [DOI] [PubMed] [Google Scholar]
  • 16. Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The diabetes mellitus‐atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020;21(5):1835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Cangkrama M, Wietecha M, Werner S. Wound repair, scar formation, and cancer: converging on activin. Trends Mol Med. 2020;26(12):1107‐1117. [DOI] [PubMed] [Google Scholar]
  • 18. Ding X, Tang Q, Xu Z, et al. Challenges and innovations in treating chronic and acute wound infections: from basic science to clinical practice. Burns Dent Traumatol. 2022;10:tkac014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Hurlow J, Bowler PG. Acute and chronic wound infections: microbiological, immunological, clinical and therapeutic distinctions. J Wound Care. 2022;31(5):436‐445. [DOI] [PubMed] [Google Scholar]
  • 20. Kim YS, Sung DK, Kong WH, Kim H, Hahn SK. Synergistic effects of hyaluronate—epidermal growth factor conjugate patch on chronic wound healing. Biomater Sci. 2018;6(5):1020‐1030. [DOI] [PubMed] [Google Scholar]
  • 21. Bauer SM, Bauer RJ, Velazquez OC. Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. Vasc Endovascular Surg. 2005;39(4):293‐306. [DOI] [PubMed] [Google Scholar]
  • 22. Schurmann C, Linke A, Engelmann‐Pilger K, et al. The dipeptidyl peptidase‐4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic Ob/Ob mice. J Pharmacol Exp Ther. 2012;342(1):71‐80. [DOI] [PubMed] [Google Scholar]
  • 23. Yu CO, Leung KS, Fung KP, et al. The characterization of a full‐thickness excision open foot wound model in n5‐streptozotocin (STZ)‐induced type 2 diabetic rats that mimics diabetic foot ulcer in terms of reduced blood circulation, higher C‐reactive protein, elevated inflammation, and reduced cell proliferation. Exp Anim. 2017;66(3):259‐269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Davis SC, Martinez L, Kirsner R. The diabetic foot: the importance of biofilms and wound bed preparation. Curr Diab Rep. 2006;6(6):439‐445. [DOI] [PubMed] [Google Scholar]
  • 25. Shiel RE, Mooney CT. Insulins for the long term management of diabetes mellitus in dogs: a review. Canine Med Genet. 2022;9(1):1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Darby IA, Bisucci T, Hewitson TD, MacLellan DG. Apoptosis is increased in a model of diabetes‐impaired wound healing in genetically diabetic mice. Int J Biochem Cell Biol. 1997;29(1):191‐200. [DOI] [PubMed] [Google Scholar]
  • 27. Anderson S, Das H. Cutaneous wound generation in diabetic NOD/SCID mice and the use of nanofiber‐expanded hematopoietic stem cell therapy. Methods Mol Biol. 2021;2193:41‐48. [DOI] [PubMed] [Google Scholar]
  • 28. Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the mouse. Science. 1966;153(3740):1127‐1128. [DOI] [PubMed] [Google Scholar]
  • 29. Yan Y, Liu X, Zhuang Y, et al. Pien Tze Huang accelerated wound healing by inhibition of abnormal fibroblast apoptosis in streptozotocin induced diabetic mice. J Ethnopharmacol. 2020;261:113203. [DOI] [PubMed] [Google Scholar]
  • 30. Wang P, Theocharidis G, Vlachos IS, et al. Exosomes derived from epidermal stem cells improve diabetic wound healing. J Invest Dermatol. 2022;142(9):2508‐2517 e13. [DOI] [PubMed] [Google Scholar]
  • 31. Singh K, Maity P, Koroma AK, et al. Angiogenin released from ABCB5(+) stromal precursors improves healing of diabetic wounds by promoting angiogenesis. J Invest Dermatol. 2022;142(6):1725‐1736 e10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Qi L, Ahmadi AR, Huang J, et al. Major improvement in wound healing through pharmacologic mobilization of stem cells in severely diabetic rats. Diabetes. 2020;69(4):699‐712. [DOI] [PubMed] [Google Scholar]
  • 33. Zhao WN, Xu SQ, Liang JF, et al. Endothelial progenitor cells from human fetal aorta cure diabetic foot in a rat model. Metabolism. 2016;65(12):1755‐1767. [DOI] [PubMed] [Google Scholar]
  • 34. Shin HS, Oh HY. The effect of platelet‐rich plasma on wounds of OLETF rats using expression of matrix Metalloproteinase‐2 and ‐9 mRNA. Arch Plast Surg. 2012;39(2):106‐112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Slavkovsky R, Kohlerova R, Tkacova V, et al. Zucker diabetic fatty rat: a new model of impaired cutaneous wound repair with type II diabetes mellitus and obesity. Wound Repair Regen. 2011;19(4):515‐525. [DOI] [PubMed] [Google Scholar]
  • 36. Wolak M, Staszewska T, Juszczak M, Galdyszynska M, Bojanowska E. Anti‐inflammatory and pro‐healing impacts of exendin‐4 treatment in Zucker diabetic rats: effects on skin wound fibroblasts. Eur J Pharmacol. 2019;842:262‐269. [DOI] [PubMed] [Google Scholar]
  • 37. Lenzen S. Animal models of human type 1 diabetes for evaluating combination therapies and successful translation to the patient with type 1 diabetes. Diabetes Metab Res Rev. 2017;33(7). [DOI] [PubMed] [Google Scholar]
  • 38. Mullen Y. Development of the nonobese diabetic mouse and contribution of animal models for understanding type 1 diabetes. Pancreas. 2017;46(4):455‐466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Wang B, Chandrasekera PC, Pippin JJ. Leptin‐ and leptin receptor‐deficient rodent models: relevance for human type 2 diabetes. Curr Diabetes Rev. 2014;10(2):131‐145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Islam MS. Animal models of diabetic neuropathy: progress since 1960s. J Diabetes Res. 2013;2013:149452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Pitale PM, Gorbatyuk MS. Diabetic retinopathy: from animal models to cellular signaling. Int J Mol Sci. 2022;23(3):1487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Michaels J t, Churgin SS, Blechman KM, et al. db/db mice exhibit severe wound‐healing impairments compared with other murine diabetic strains in a silicone‐splinted excisional wound model. Wound Repair Regen. 2007;15(5):665‐670. [DOI] [PubMed] [Google Scholar]
  • 43. Nakanishi K. Hypertension in obese Zucker rat. Nihon Rinsho. 2006;64(Suppl 5):296‐299. [PubMed] [Google Scholar]
  • 44. Hirose H, Lee YH, Inman LR, Nagasawa Y, Johnson JH, Unger RH. Defective fatty acid‐mediated beta‐cell compensation in Zucker diabetic fatty rats. Pathogenic implications for obesity‐dependent diabetes. J Biol Chem. 1996;271(10):5633‐5637. [DOI] [PubMed] [Google Scholar]
  • 45. Hughes SJ, Suzuki K, Goto Y. The role of islet secretory function in the development of diabetes in the GK Wistar rat. Diabetologia. 1994;37(9):863‐870. [DOI] [PubMed] [Google Scholar]
  • 46. Watanabe S, Matsumoto T, Taguchi K, Kobayashi T. Relationship between PDK1 and contraction in carotid arteries in Goto‐Kakizaki rat, a spontaneous type 2 diabetic animal model. Can J Physiol Pharmacol. 2017;95(4):459‐462. [DOI] [PubMed] [Google Scholar]
  • 47. Yue Y, Liu X, Pang L, et al. Astragalus polysaccharides/PVA nanofiber membranes containing Astragaloside IV‐loaded liposomes and their potential use for wound healing. Evid Based Complement Alternat Med. 2022;2022:9716271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Akhtar F, Khan AU, Qazi B, et al. A nano phototheranostic approach of toluidine blue conjugated gold silver core shells mediated photodynamic therapy to treat diabetic foot ulcer. Sci Rep. 2021;11(1):24464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Lin CJ, Lan YM, Ou MQ, Ji LQ, Lin SD. Expression of miR‐217 and HIF‐1alpha/VEGF pathway in patients with diabetic foot ulcer and its effect on angiogenesis of diabetic foot ulcer rats. J Endocrinol Invest. 2019;42(11):1307‐1317. [DOI] [PubMed] [Google Scholar]
  • 50. Yang X, Cao Z, Wu P, Li Z. Effect and mechanism of the Bruton tyrosine kinase (Btk) inhibitor ibrutinib on rat model of diabetic foot ulcers. Med Sci Monit. 2019;25:7951‐7957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Li X, Xie X, Lian W, et al. Exosomes from adipose‐derived stem cells overexpressing Nrf2 accelerate cutaneous wound healing by promoting vascularization in a diabetic foot ulcer rat model. Exp Mol Med. 2018;50(4):1‐14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. He M, Tu L, Shu R, et al. Long noncoding RNA CASC2 facilitated wound healing through miRNA‐155/HIF‐1alpha in diabetic foot ulcers. Contrast Media Mol Imaging. 2022;2022:6291497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Li S, Wang X, Chen J, et al. Calcium ion cross‐linked sodium alginate hydrogels containing deferoxamine and copper nanoparticles for diabetic wound healing. Int J Biol Macromol. 2022;202:657‐670. [DOI] [PubMed] [Google Scholar]
  • 54. Nehete MN, Nipanikar S, Kanjilal AS, Kanjilal S, Tatke PA. Comparative efficacy of two polyherbal creams with framycetin sulfate on diabetic wound model in rats. J Ayurveda Integr Med. 2016;7(2):83‐87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Eo H, Lee HJ, Lim Y. Ameliorative effect of dietary genistein on diabetes induced hyper‐inflammation and oxidative stress during early stage of wound healing in alloxan induced diabetic mice. Biochem Biophys Res Commun. 2016;478(3):1021‐1027. [DOI] [PubMed] [Google Scholar]
  • 56. Park NY, Lim Y. Short term supplementation of dietary antioxidants selectively regulates the inflammatory responses during early cutaneous wound healing in diabetic mice. Nutr Metab (Lond). 2011;8(1):80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Sun X, Wang X, Zhao Z, Chen J, Li C, Zhao G. Paeoniflorin accelerates foot wound healing in diabetic rats though activating the Nrf2 pathway. Acta Histochem. 2020;122(8):151649. [DOI] [PubMed] [Google Scholar]
  • 58. Song FC, Yuan JQ, Zhu MD, et al. High glucose represses the proliferation of tendon fibroblasts by inhibiting autophagy activation in tendon injury. Biosci Rep. 2022;42(3):BSR20210640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Li B, Luan S, Chen J, et al. The MSC‐derived Exosomal lncRNA H19 promotes wound healing in diabetic foot ulcers by upregulating PTEN via MicroRNA‐152‐3p. Mol Ther Nucleic Acids. 2020;19:814‐826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Ouyang L, Qiu D, Fu X, et al. Overexpressing HPGDS in adipose‐derived mesenchymal stem cells reduces inflammatory state and improves wound healing in type 2 diabetic mice. Stem Cell Res Ther. 2022;13(1):395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61. Haghani F, Arabnezhad MR, Mohammadi S, Ghaffarian‐Bahraman A. Aloe vera and Streptozotocin‐induced diabetes mellitus. Rev Bras Farmacogn. 2022;32(2):174‐187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Qiu F, Meng T, Chen Q, et al. Fenofibrate‐loaded biodegradable nanoparticles for the treatment of experimental diabetic retinopathy and neovascular age‐related macular degeneration. Mol Pharm. 2019;16(5):1958‐1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. He M, Long P, Yan W, et al. ALDH2 attenuates early‐stage STZ‐induced aged diabetic rats retinas damage via Sirt1/Nrf2 pathway. Life Sci. 2018;215:227‐235. [DOI] [PubMed] [Google Scholar]
  • 64. Feng Y, Wang R, Xu J, et al. Hydrogen‐rich saline prevents early neurovascular dysfunction resulting from inhibition of oxidative stress in STZ‐diabetic rats. Curr Eye Res. 2013;38(3):396‐404. [DOI] [PubMed] [Google Scholar]
  • 65. Liao PL, Lin CH, Li CH, et al. Anti‐inflammatory properties of shikonin contribute to improved early‐stage diabetic retinopathy. Sci Rep. 2017;7:44985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66. Ighodaro OM, Adeosun AM, Akinloye OA. Alloxan‐induced diabetes, a common model for evaluating the glycemic‐control potential of therapeutic compounds and plants extracts in experimental studies. Medicina (Kaunas). 2017;53(6):365‐374. [DOI] [PubMed] [Google Scholar]
  • 67. Rais N, Ved A, Ahmad R, et al. Model of streptozotocin‐nicotinamide induced type 2 diabetes: a comparative review. Curr Diabetes Rev. 2022;18(8):e171121198001. [DOI] [PubMed] [Google Scholar]
  • 68. Haba D, Arakawa T. Chronological changes in rat heel skin following depressurization of pressure ulcer‐like dermal lesions. Acta Histochem. 2020;122(1):151459. [DOI] [PubMed] [Google Scholar]
  • 69. Prabodha LBL, Sirisena ND, Dissanayake VHW. Susceptible and prognostic genetic factors associated with diabetic peripheral neuropathy: a comprehensive literature review. Int J Endocrinol. 2018;2018:8641942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70. Maione AG, Brudno Y, Stojadinovic O, et al. Three‐dimensional human tissue models that incorporate diabetic foot ulcer‐derived fibroblasts mimic in vivo features of chronic wounds. Tissue Eng Part C Methods. 2015;21(5):499‐508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71. Yilmaz Ozdogan C, Kenar H, Davun KE, Yucel D, Doger E, Alagoz S. Anin vitro3D diabetic human skin model from diabetic primary cells. Biomed Mater. 2020;16:015027. [DOI] [PubMed] [Google Scholar]
  • 72. Zhao F, Liu Y, Song T, et al. A chitosan‐based multifunctional hydrogel containing in situ rapidly bioreduced silver nanoparticles for accelerating infected wound healing. J Mater Chem B. 2022;10(13):2135‐2147. [DOI] [PubMed] [Google Scholar]
  • 73. Dumville JC, Deshpande S, O'Meara S, Speak K. Hydrocolloid dressings for healing diabetic foot ulcers. Cochrane Database Syst Rev. 2013;8:CD009099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Yang Y, Li Y, Pan Q, et al. Tibial cortex transverse transport accelerates wound healing via enhanced angiogenesis and immunomodulation. Bone Joint Res. 2022;11(4):189‐199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75. Deng ZB, Poliakov A, Hardy RW, et al. Adipose tissue exosome‐like vesicles mediate activation of macrophage‐induced insulin resistance. Diabetes. 2009;58(11):2498‐2505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Yan J, Liang J, Cao Y, et al. Efficacy of topical and systemic transplantation of mesenchymal stem cells in a rat model of diabetic ischemic wounds. Stem Cell Res Ther. 2021;12(1):220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77. Andre‐Levigne D, Modarressi A, Pignel R, Bochaton‐Piallat ML, Pittet‐Cuenod B. Hyperbaric oxygen therapy promotes wound repair in ischemic and hyperglycemic conditions, increasing tissue perfusion and collagen deposition. Wound Repair Regen. 2016;24(6):954‐965. [DOI] [PubMed] [Google Scholar]
  • 78. Nishimoto S, Kawai K, Tsumano T, Fukuda K, Fujiwara T, Kakibuchi M. Impacts of bone marrow aspirate and peripheral blood derived platelet‐rich plasma on the wound healing in chronic ischaemic limb. J Plast Surg Hand Surg. 2013;47(3):169‐174. [DOI] [PubMed] [Google Scholar]
  • 79. Choo HC, Nosaka K, Peiffer JJ, Ihsan M, Yeo CC, Abbiss CR. Reliability of laser doppler, near‐infrared spectroscopy and doppler ultrasound for peripheral blood flow measurements during and after exercise in the heat. J Sports Sci. 2017;35(17):1715‐1723. [DOI] [PubMed] [Google Scholar]
  • 80. Jia L, Zheng P, Wang H, Kang L, Wu H, Fu X. VEGF alleviates lower limb ischemia in diabetic mice by altering muscle fiber types. Exp Ther Med. 2022;23(4):251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81. Jung CH, Cho YY, Choi D, Kim BY, Kim CH, Mok JO. Relationship of sarcopenia with microcirculation measured by skin perfusion pressure in patients with type 2 diabetes. Endocrinol Metab (Seoul). 2020;35(3):578‐586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82. Rodrigues LM, Rocha C, Ferreira H, Silva H. Different lasers reveal different skin microcirculatory flowmotion—data from the wavelet transform analysis of human hindlimb perfusion. Sci Rep. 2019;9(1):16951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83. Jin S, Zhang M, Gao Y, Zhang X, Cui G, Zhang Y. The efficacy of Jing Wan Hong ointment for nerve injury diabetic foot ulcer and its mechanisms. J Diabetes Res. 2014;2014:259412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84. Cudlip SA, Howe FA, Griffiths JR, Bell BA. Magnetic resonance neurography of peripheral nerve following experimental crush injury, and correlation with functional deficit. J Neurosurg. 2002;96(4):755‐759. [DOI] [PubMed] [Google Scholar]
  • 85. Lu L, Liu D, Ying J, et al. Denervation affected skin wound healing in a modified rat model. Int J Low Extrem Wounds. 2022;153473462210907. [DOI] [PubMed] [Google Scholar]
  • 86. Shu B, Xie JL, Xu YB, et al. Effects of skin‐derived precursors on wound healing of denervated skin in a nude mouse model. Int J Clin Exp Pathol. 2015;8(3):2660‐2669. [PMC free article] [PubMed] [Google Scholar]
  • 87. Karkada G, Maiya GA, Arany P, Rao M, Adiga S, Kamath SU. Effect of Photobiomodulation therapy on oxidative stress markers in healing dynamics of diabetic neuropathic wounds in Wistar rats. Cell Biochem Biophys. 2022;80(1):151‐160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88. Anju M, Chacko L, Chettupalli Y, Maiya AG, Saleena Ummer V. Effect of low level laser therapy on serum vitamin D and magnesium levels in patients with diabetic peripheral neuropathy—a pilot study. Diabetes Metab Syndr. 2019;13(2):1087‐1091. [DOI] [PubMed] [Google Scholar]
  • 89. Calcutt NA. Diabetic neuropathy and neuropathic pain: a (con)fusion of pathogenic mechanisms? Pain. 2020;161(Suppl 1):S65‐S86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90. Price BL, Lovering AM, Bowling FL, Dobson CB. Development of a novel collagen wound model to simulate the activity and distribution of antimicrobials in soft tissue during diabetic foot infection. Antimicrob Agents Chemother. 2016;60(11):6880‐6889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91. Gomes D, Santos R, Reis S, et al. Pexiganan in combination with nisin to control polymicrobial diabetic foot infections. Antibiotics (Basel). 2020;9(3):128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92. Angrup A, Sood A, Ray P, Bala K. Clinical anaerobic infections in an Indian tertiary care hospital: a two‐year retrospective study. Anaerobe. 2022;73:102482. [DOI] [PubMed] [Google Scholar]
  • 93. Karthik S, Babu L, Joseph M, Bhatt A, Babu T. Microbiology of diabetic foot osteomyelitis—is it geographically variable? Foot (Edinb). 2022;52:101878. [DOI] [PubMed] [Google Scholar]
  • 94. Kifelew LG, Warner MS, Morales S, et al. Efficacy of phage cocktail AB‐SA01 therapy in diabetic mouse wound infections caused by multidrug‐resistant Staphylococcus aureus. BMC Microbiol. 2020;20(1):204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95. Rich J, Lee JC. The pathogenesis of Staphylococcus aureus infection in the diabetic NOD mouse. Diabetes. 2005;54(10):2904‐2910. [DOI] [PubMed] [Google Scholar]
  • 96. Chhibber S, Kaur T, Sandeep K. Co‐therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections. PloS One. 2013;8(2):e56022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97. El‐Naggar MY, Gohar YM, Sorour MA, Waheeb MG. Hydrogel dressing with a Nano‐formula against methicillin‐resistant Staphylococcus aureus and Pseudomonas aeruginosa diabetic foot bacteria. J Microbiol Biotechnol. 2016;26(2):408‐420. [DOI] [PubMed] [Google Scholar]
  • 98. Rasigade JP, Dunyach‐Remy C, Sapin A, et al. A prophage in diabetic foot ulcer‐colonizing Staphylococcus aureus impairs invasiveness by limiting intracellular growth. J Infect Dis. 2016;214(10):1605‐1608. [DOI] [PubMed] [Google Scholar]
  • 99. Huon JF, Montassier E, Leroy AG, et al. Phages versus antibiotics to treat infected diabetic wounds in a mouse model: a microbiological and microbiotic evaluation. mSystems. 2020;5(6):e00542‐20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100. Albac S, Medina M, Labrousse D, et al. Efficacy of bacteriophages in a Staphylococcus aureus nondiabetic or diabetic foot infection murine model. Antimicrob Agents Chemother. 2020;64(2):e01870‐19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101. Snow DE, Everett J, Mayer G, et al. The presence of biofilm structures in atherosclerotic plaques of arteries from legs amputated as a complication of diabetic foot ulcers. J Wound Care. 2016;25(2):S16‐S22. [DOI] [PubMed] [Google Scholar]
  • 102. Al‐Joufi FA, Aljarallah KM, Hagras SA, et al. Microbial spectrum, antibiotic susceptibility profile, and biofilm formation of diabetic foot infections (2014–18): a retrospective multicenter analysis. 3 Biotech. 2020;10(7):325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103. Zhao G, Usui ML, Underwood RA, et al. Time course study of delayed wound healing in a biofilm‐challenged diabetic mouse model. Wound Repair Regen. 2012;20(3):342‐352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104. Nguyen AT, Oglesby‐Sherrouse AG. Interactions between Pseudomonas aeruginosa and Staphylococcus aureus during co‐cultivations and polymicrobial infections. Appl Microbiol Biotechnol. 2016;100(14):6141‐6148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105. Kaltalioglu K, Balabanli B, Coskun‐Cevher S. Phenolic, antioxidant, antimicrobial, and In‐vivo wound healing properties of Potentilla erecta L. root extract in diabetic rats. Iran J Pharm Res. 2020;19(4):264‐274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106. Zhang Y, Zhang P, Gao X, Chang L, Chen Z, Mei X. Preparation of exosomes encapsulated nanohydrogel for accelerating wound healing of diabetic rats by promoting angiogenesis. Mater Sci Eng C Mater Biol Appl. 2021;120:111671. [DOI] [PubMed] [Google Scholar]
  • 107. Chen RF, Lin YN, Liu KF, et al. The acceleration of diabetic wound healing by low‐intensity extracorporeal shockwave involves in the GSK‐3beta pathway. Biomedicine. 2020;9(1):21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108. Randeria PS, Seeger MA, Wang XQ, et al. siRNA‐based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown. Proc Natl Acad Sci USA. 2015;112(18):5573‐5578. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109. Hsu SH, Hsieh PS. Self‐assembled adult adipose‐derived stem cell spheroids combined with biomaterials promote wound healing in a rat skin repair model. Wound Repair Regen. 2015;23(1):57‐64. [DOI] [PubMed] [Google Scholar]
  • 110. Galiano RD, Michaels J t, Dobryansky M, Levine JP, Gurtner GC. Quantitative and reproducible murine model of excisional wound healing. Wound Repair Regen. 2004;12(4):485‐492. [DOI] [PubMed] [Google Scholar]
  • 111. Dunn L, Prosser HC, Tan JT, Vanags LZ, Ng MK, Bursill CA. Murine model of wound healing. J Vis Exp. 2013;75:e50265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112. Danigo A, Nasser M, Bessaguet F, et al. Candesartan restores pressure‐induced vasodilation and prevents skin pressure ulcer formation in diabetic mice. Cardiovasc Diabetol. 2015;14:26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113. Langer S, Beescho C, Ring A, Dorfmann O, Steinau HU, Spindler N. A new in vivo model using a dorsal skinfold chamber to investigate microcirculation and angiogenesis in diabetic wounds. GMS Interdiscip Plast Reconstr Surg DGPW. 2016;5:Doc09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114. Yang X, Yang R, Chen M, et al. KGF‐2 and FGF‐21 poloxamer 407 hydrogel coordinates inflammation and proliferation homeostasis to enhance wound repair of scalded skin in diabetic rats. BMJ Open Diabetes Res Care. 2020;8(1):e001009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115. Wood FM, Giles N, Stevenson A, Rea S, Fear M. Characterisation of the cell suspension harvested from the dermal epidermal junction using a ReCell(R) kit. Burns. 2012;38(1):44‐51. [DOI] [PubMed] [Google Scholar]
  • 116. Lan CC, Wu CS, Kuo HY, Huang SM, Chen GS. Hyperglycaemic conditions hamper keratinocyte locomotion via sequential inhibition of distinct pathways: new insights on poor wound closure in patients with diabetes. Br J Dermatol. 2009;160(6):1206‐1214. [DOI] [PubMed] [Google Scholar]
  • 117. Lyons TJ, Basu A. Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers. Transl Res. 2012;159(4):303‐312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118. Maione AG, Smith A, Kashpur O, et al. Altered ECM deposition by diabetic foot ulcer‐derived fibroblasts implicates fibronectin in chronic wound repair. Wound Repair Regen. 2016;24(4):630‐643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119. Hajati Ziabari A, Asadi Heris M, Mohammad Doodmani S, Jahandideh A, Koorehpaz K, Mohammadi R. Cinnamon nanoparticles loaded on chitosan‐ gelatin nanoparticles enhanced burn wound healing in diabetic foot ulcers in rats. Int J Low Extrem Wounds. 2022;153473462211012. [DOI] [PubMed] [Google Scholar]
  • 120. Liang Y, Li M, Yang Y, Qiao L, Xu H, Guo B. pH/glucose dual responsive metformin release hydrogel dressings with adhesion and self‐healing via dual‐dynamic bonding for athletic diabetic foot wound healing. ACS Nano. 2022;16(2):3194‐3207. [DOI] [PubMed] [Google Scholar]
  • 121. Gokce EH, Tuncay Tanriverdi S, Eroglu I, et al. Wound healing effects of collagen‐laminin dermal matrix impregnated with resveratrol loaded hyaluronic acid‐DPPC microparticles in diabetic rats. Eur J Pharm Biopharm. 2017;119:17‐27. [DOI] [PubMed] [Google Scholar]
  • 122. Kanda N, Morimoto N, Ayvazyan AA, et al. Evaluation of a novel collagen‐gelatin scaffold for achieving the sustained release of basic fibroblast growth factor in a diabetic mouse model. J Tissue Eng Regen Med. 2014;8(1):29‐40. [DOI] [PubMed] [Google Scholar]
  • 123. Krasilnikova OA, Baranovskii DS, Lyundup AV, Shegay PV, Kaprin AD, Klabukov ID. Stem and somatic cell monotherapy for the treatment of diabetic foot ulcers: review of clinical studies and mechanisms of action. Stem Cell Rev Rep. 2022;18(6):1974‐1985. [DOI] [PubMed] [Google Scholar]
  • 124. Sim E, Cullis PR, Richards RE. Physical studies on phosphonium phosphatidylcholine. A unique [31P]phosphorus nuclear‐magnetic‐resonance probe for model and biological membranes. Biochem J. 1975;151(3):555‐560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125. Sener LT, Albeniz I. Challenge of mesenchymal stem cells against diabetic foot ulcer. Curr Stem Cell Res Ther. 2015;10(6):530‐534. [DOI] [PubMed] [Google Scholar]
  • 126. Hamada M, Iwata T, Kato Y, et al. Xenogeneic transplantation of human adipose‐derived stem cell sheets accelerate angiogenesis and the healing of skin wounds in a Zucker diabetic fatty rat model of obese diabetes. Regen Ther. 2017;6:65‐73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127. Mellin TN, Cashen DE, Ronan JJ, Murphy BS, DiSalvo J, Thomas KA. Acidic fibroblast growth factor accelerates dermal wound healing in diabetic mice. J Invest Dermatol. 1995;104(5):850‐855. [DOI] [PubMed] [Google Scholar]
  • 128. Peplow PV, Baxter GD. Gene expression and release of growth factors during delayed wound healing: a review of studies in diabetic animals and possible combined laser phototherapy and growth factor treatment to enhance healing. Photomed Laser Surg. 2012;30(11):617‐636. [DOI] [PubMed] [Google Scholar]
  • 129. Choi SM, Lee KM, Kim HJ, et al. Effects of structurally stabilized EGF and bFGF on wound healing in type I and type II diabetic mice. Acta Biomater. 2018;66:325‐334. [DOI] [PubMed] [Google Scholar]
  • 130. Baltazar T, Merola J, Catarino C, et al. Three dimensional bioprinting of a vascularized and Perfusable skin graft using human keratinocytes, fibroblasts, pericytes, and endothelial cells. Tissue Eng Part A. 2020;26(5–6):227‐238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131. Kesavan R, Sheela Sasikumar C, Narayanamurthy VB, Rajagopalan A, Kim J. Management of Diabetic Foot Ulcer with MA‐ECM (minimally manipulated autologous extracellular matrix) using 3D bioprinting technology—an innovative approach. Int J Low Extrem Wounds. 2021;153473462110456. [DOI] [PubMed] [Google Scholar]
  • 132. Turner PR, Murray E, McAdam CJ, McConnell MA, Cabral JD. Peptide chitosan/dextran Core/Shell vascularized 3D constructs for wound healing. ACS Appl Mater Interfaces. 2020;12(29):32328‐32339. [DOI] [PubMed] [Google Scholar]
  • 133. Zhang G, Varkey M, Wang Z, Xie B, Hou R, Atala A. ECM concentration and cell‐mediated traction forces play a role in vascular network assembly in 3D bioprinted tissue. Biotechnol Bioeng. 2020;117(4):1148‐1158. [DOI] [PubMed] [Google Scholar]
  • 134. Ozdogan CY, Kenar H, Davun KE, Yucel D, Doger E, Alagoz S. An in vitro 3D diabetic human skin model from diabetic primary cells. Biomed Mater. 2020;16(1):015027. [DOI] [PubMed] [Google Scholar]
  • 135. Gerami‐Naini B, Smith A, Maione AG, et al. Generation of induced pluripotent stem cells from diabetic foot ulcer fibroblasts using a nonintegrative Sendai virus. Cell Reprogram. 2016;18(4):214‐223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 136. Lu Y, Ding X, Qi F, et al. Quyu Shengji formula facilitates diabetic wound healing via inhibiting the expression of prostaglandin transporter. Evid Based Complement Alternat Med. 2021;2021:8849935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137. Huang R, Hu X, Li W, et al. Zizhu ointment accelerates wound‐healing of diabetic ulcers through promoting M2 macrophage polarization via downregulating the Notch4 signaling pathway. Comput Intell Neurosci. 2022;2022:5173836. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 138. Rai V, Moellmer R, Agrawal DK. Clinically relevant experimental rodent models of diabetic foot ulcer. Mol Cell Biochem. 2022;477(4):1239‐1247. [DOI] [PubMed] [Google Scholar]
  • 139. Ahmed R, Afreen A, Tariq M, et al. Bone marrow mesenchymal stem cells preconditioned with nitric‐oxide‐releasing chitosan/PVA hydrogel accelerate diabetic wound healing in rabbits. Biomed Mater. 2021;16(3):035014. [DOI] [PubMed] [Google Scholar]
  • 140. Grada A, Mervis J, Falanga V. Research techniques made simple: animal models of wound healing. J Invest Dermatol. 2018;138(10):2095‐2105 e1. [DOI] [PubMed] [Google Scholar]
  • 141. Richardson R, Metzger M, Knyphausen P, et al. Re‐epithelialization of cutaneous wounds in adult zebrafish combines mechanisms of wound closure in embryonic and adult mammals. Development. 2016;143(12):2077‐2088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 142. Ashcroft GS, Horan MA, Ferguson MW. Aging is associated with reduced deposition of specific extracellular matrix components, an upregulation of angiogenesis, and an altered inflammatory response in a murine incisional wound healing model. J Invest Dermatol. 1997;108(4):430‐437. [DOI] [PubMed] [Google Scholar]
  • 143. Wang S, Shi M, Zhou J, Wang W, Zhang Y, Li Y. Circulating Exosomal miR‐181b‐5p promoted cell senescence and inhibited angiogenesis to impair diabetic foot ulcer via the nuclear factor erythroid 2‐related factor 2/heme Oxygenase‐1 pathway. Front Cardiovasc Med. 2022;9:844047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 144. Nunan R, Harding KG, Martin P. Clinical challenges of chronic wounds: searching for an optimal animal model to recapitulate their complexity. Dis Model Mech. 2014;7(11):1205‐1213. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data sharing is not applicable for this article.


Articles from International Wound Journal are provided here courtesy of Wiley

RESOURCES